Active, not recruitingPhase 3NCT05018286

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: VectivBio AG
Principal Investigator: Tomasz Masior
VectivBio AG
Intervention: Apraglutide(drug)
Enrollment: 158 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2027

Study locations (30)

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
Gastroenterology Group of Naples, Naples, Florida, United States
Northwestern University - Chicago, Chicago, Illinois, United States
Henry Ford Health System, Detroit, Michigan, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Mount Sinai Medical Center, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
University of Washington Medical Center, Seattle, Washington, United States
University Hospital Fundacion Favaloro, Buenos Aires, Argentina
University Hospital Brussels, Brussels, Belgium
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05018286 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials